Guard Therapeutics announced that Sara Thuresson has been recruited to a newly created position as Head of Clinical Operations. She held a similar position at Oncopeptides before joining Guard Therapeutics and will take up her new post on 24 May 2021.She has more than 15 years' experience from a series of key positions in clinical drug development at companies including IQVIA, Glionova and Wilson Therapeutics. Prior to her new appointment she was Clinical Operations Director at Oncopeptides. Sara Thuresson will be part of Guard Therapeutics' management team and will report to the company's CEO.